Hi @Champee Whats your thoughts on the following, We may see...

Hi @Champee

Whats your thoughts on the following, We may see some Revenues from China last 2017 early 2018, with Enlitics value growing every day,

From Announcement above
Outlook
The return of stronger Medicare growth rates in the 5%-6% range provide a platform for revenue growth in the FY18 period. Revenue from Victorian operations slightly outpaced Medicare growth rates during the FY17 period, and this has continued early in the FY18 year. This growth provides a upside opportunity for FY18 earnings, as guidance was based on more moderate 3.5% revenue growth. Similarly, new acquisitions were not included in the FY18 guidance.

China JV time frame
Capitol will own a 30% stake in the JV contributing RMB3 million (approximately AUD$600,000), CITIC Pharmaceutical will own 60%, Zhouxin will own 10%, and combined, will contribute RMB7 million. The agreement also provides Capitol with an option at Capitol’s discretion to take ownership stakes in new diagnostic imaging centers to be under management. As the JV will establish greenfield imaging centres it is not expected to generate earnings during the FY17 period.
CAMI’s early diagnostic imaging centers are planned for opening in 2017 in cities where CITIC already own hospitals that will generate patient referrals.

https://hotcopper.com.au/threads/an...lting-clinic-management.3238721/#.WaJqECig_tR

Financial report 2017

Our expansion in China with equity Joint Venture partners (“JV”) CITIC Pharmaceutical (Shenzhen) Co., Ltd (“CITIC Pharmaceutical”) and Xiamen Zhouxin Medical Image Co., Ltd ("Zhouxin") will provide consulting and clinic management services to a network of independent imaging clinics to be created by CITIC and Zhouxin across mainland China. We are well progressed with the necessary approvals and expect to finalise our ~ $600,000 funding of the venture in coming months.

There has also been substantial progress at Enlitic Inc (our US medical deep learning investment) with changes to the board and management that have resulted in faster than expected progress both in development and early commercialisation efforts. We plan to use Enlitic’s Chest X-ray tool in some Capital Radiology clinics in Victoria as a post reporting Quality Assurance tool (subject to TGA registration). Enlitic also have numerous developing commercial and research partnerships across a number of countries and respected institutions.The result of these efforts is that the market capitalisation during August 2017 has increased between 4 and 5 times its value in November 2016, and the business is positioned with substantial capacity for growth.